Eisai Co. Ltd Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (139)

Electronic Access - Single User License $800 Buy Now
CD-ROM Mail Delivery $1200Buy Now
Hard Copy Mail Delivery $1200 Buy Now
Electronic Access - Multi-User License $1600 Buy Now


“Eisai Co. Ltd Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Eisai Co. Ltd. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “31” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 15 cancer drugs by Eisai Co. Ltd. which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Eisai Co. Ltd Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Eisai Co. Ltd Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Eisai Co. Ltd. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “31” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 15 cancer drugs by Eisai Co. Ltd. which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Eisai Co. Ltd Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Eisai

  1.1 Business Overview

  1.2 Eisai Cancer Pipeline Overview

 

2. Eisai Cancer Drugs in Research Phase

  2.1 Modified Chlorotoxin Radiotherapeutics – TransMolecular

  2.2 Recombinant Bifidobacterium Anticancer Therapeutics - Anaeropharma Science/Eisai

  2.3 Farletuzumab Radioimmunotherapy - Morphotek/University of Gothenburg

  2.4 Protein-Protein Inhibitors - Eisai/Paoli Calmettes

  2.5 Cancer Therapies - H3 Biomedicine/Foundation Medicine

  2.6 Antibody Drug Conjugates - Concortis/Morphotek

 

3. Eisai Cancer Drugs in Preclinical Phase

  3.1 MORAb 022

  3.2 Cancer Therapies - H3 Biomedicine/Eisai

  3.3 APX 3330

  3.4 Immunoconjugated Micelles - Eisai/Nanocarrier

  3.5 212 Pb Ontuxizumab Conjugate - AREVA Med/Morphotek

  3.6 Protein Kinase Inhibitors - H3 Biomedicine/Selvita

  3.7 Monoclonal Antibodies - Human Genome Sciences/KAN Research Institute/Morphotek

  3.8 Anticancer Monoclonal Antibodies – Morphotek

  3.9 Monoclonal Antibody Therapeutics - Human monoclonal international/Morphotek

  3.10 PARP Inhibitors – Eisai

  3.11 Antineoplastic Monoclonal Antibodies - Morphotek/John Wayne Cancer Institute

 

4. Eisai Cancer Drugs in Clinical Phase

  4.1 EPZ 6438 Companion Diagnostic - Eisai/Epizyme/Roche

 

5. Eisai Cancer Drugs in Phase-I

  5.1 RAD 1901

  5.2 Eribulin Liposomal

  5.3 MORAb 066

  5.4 E 7046

  5.5 H3B 6527

  5.6 E 7090

 

6. Eisai Cancer Drugs in Phase-I/II

  6.1 E 6201

  6.2 PRI 724

 

7. Eisai Cancer Drugs in Phase-II

  7.1 Tazemetostat

  7.2 Ontuxizumab

  7.3 E 7820

 

8. Eisai Cancer Drugs in Phase-III

  8.1 Pegylated Recombinant Human Hyaluronidase – Halozyme

  8.2 Farletuzumab

 

9. Marketed Cancer Drugs by Eisai

  9.1 Lenvatinib (Kisplyx & Lenvima)

  9.2 Chidamide (Epidaza)

  9.3 Pembrolizumab (Keytruda)

  9.4 Eribulin (Halaven)

 9.5 Bendamustine (Bendam, Bendamus, Bentaman, Endexin, Esevaril, Innomustine, Levact, Ribomustin, Ribomustine, Ribovact, Symbenda, Treakisym & Treanda)

  9.6 Temozolomide (Temodal & Temodar)

  9.7 Decitabine (Dacogen)

  9.8 Carmustine Polifeprosan 20 Wafer (Gliadel)

  9.9 Bexarotene Topical (Targretin gel)

  9.10 Bexarotene Oral (Targretin oral)

  9.11 Denileukin Diftitox (ONTAK)

  9.12 Toremifene (Fareston)

  9.13 Altretamine (Hexalen & Hexastat)

  9.14 Doxorubicin-Eluting Beads (DC Bead, LifePearl & PRECISION Bead)

  9.15 Alitretinoin Topical (Panretin)

 

 10. No Development Reported in Cancer Drugs in Clinical Pipeline

  10.1 Amatuximab

  10.2 E 7449

  10.3 E 7016

  10.4 Targeted EZH2 Inhibitors - Epizyme/Eisai

  10.5 Monoclonal Antibody Therapeutics - Morphotek/University of Pennsylvania

  10.6 B 428

  10.7 Topoisomerase II Inhibitors – Eisai

  10.8 Proteasome Inhibitors – Eisai

  10.9 Next-Generation Wnt Signalling Pathway Inhibitors - Eisai/Verastem

  10.10 Cancer Therapeutics - Eisai/FORMA

  10.11 Cancer and Infectious Disease Monoclonal Antibodies - Morphotek/Alexion

  10.12 Anticancer Monoclonal Antibodies - Champions Oncology/Morphotek

  10.13 Monoclonal Antibody Therapeutics - Morphotek/University Hospital Heidelberg

  10.14 Cancer Therapies - Compendia Bioscience/H3 Biomedicine

 

11. Discontinued in Cancer Drugs in Clincal Pipeline

  11.1 Menatetrenone

  11.2 Irofulven

  11.3 ABT 751

  11.4 TM-601-I-131

  11.5 Indisulam

  11.6 Peretinoin – Eisai

  11.7 Golvatinib

  11.8 E 7974

  11.9 TM 601

  11.10 MORAb 028

  11.11 ZYC 300

  11.12 Monoclonal Antibody Therapeutics - Morphotek/Wistar Institute

  11.13 Tubulin Polymerisation Inhibitors – Eisai

  11.14 ER 35794

  11.15 ER 38925

  11.16 ER 69029

  11.17 ER 68203

  11.18 B 1086

  11.19 B 956

  11.20 ER 65250

  11.21 ER 34410

  11.22 B 581

 

12. Suspended in Cancer Drug in Clinical Pipeline

  12.1 E 7107  


Figure 1-1: Eisai Clinical pipeline by Phase (%)

Figure 1-2: Eisai Clinical Pipeline by Phase (Number)

Figure 1-3: Eisai Clinical Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%)

Figure 1-4: Eisai Clinical Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Number)